Compile Data Set for Download or QSAR
Report error Found 165 of ph data with Target = 'Complement factor B'
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159970(US9682968, Example-20a | US10093663, Example 20a)
Affinity DataIC50: 9nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289502(US10093663, Example 27-4a)
Affinity DataIC50: 9nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 10nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159938(US9682968, Example-17-29 | US10093663, Example 17-...)
Affinity DataIC50: 11nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159545(US9682968, Example-17-30 | US9682968, Example-17-1...)
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289488(US10093663, Example 22-2b)
Affinity DataIC50: 13nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289500(US10093663, Example 27-3a)
Affinity DataIC50: 14nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159486(US9682968, Example-17-11 | US10093663, Example 17-...)
Affinity DataIC50: 15nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289498(US10093663, Example 27-2a)
Affinity DataIC50: 15nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159312(US9682968, Example-17-1 | US10093663, Example 17-1)
Affinity DataIC50: 19nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160036(US9682968, Example-21a | US10093663, Example 21a)
Affinity DataIC50: 19nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289485(US10093663, Example 22-1a)
Affinity DataIC50: 19nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160499(US9682968, Example-36 | US10093663, Example 36)
Affinity DataIC50: 20nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289497(US10093663, Example 27-1b)
Affinity DataIC50: 22nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160500(US9682968, Example-37 | US10093663, Example 37)
Affinity DataIC50: 22nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181732(US9676728, 5 b (-)-2-(2,2,2-Trifluoro-1-(2-methoxy...)
Affinity DataIC50: 23nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159545(US9682968, Example-17-30 | US9682968, Example-17-1...)
Affinity DataIC50: 23nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159566(US9682968, Example-17-18 | US10093663, Example 17-...)
Affinity DataIC50: 27nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251874(US9475806, 8-B b) (-))
Affinity DataIC50: 30nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251876(US9475806, 9-D b) (-))
Affinity DataIC50: 30nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159311(US9682968, Example-16 | US10093663, Example 16)
Affinity DataIC50: 30nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289450(US10093663, Example 17-5 | US10093663, Example 17-...)
Affinity DataIC50: 30nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159873(US9682968, Example-17-24 | US10093663, Example 17-...)
Affinity DataIC50: 35nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159289(US9682968, Example-5-12 | US10093663, Example 5-12)
Affinity DataIC50: 37nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289451(US10093663, Example 17-3)
Affinity DataIC50: 38nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251878(US9475806, 10-B b) (-))
Affinity DataIC50: 40nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251882(US9475806, 12-D)
Affinity DataIC50: 40nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159920(US9682968, Example-17-25 | US10093663, Example 17-...)
Affinity DataIC50: 45nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160473(US9682968, Example-25a (+) | US10093663, Example 2...)
Affinity DataIC50: 47nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251873(US9475806, 7-D b) (+))
Affinity DataIC50: 50nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM182861(US9676728, 11-B b (-)-2-(2,2,2-Trifluoro-1-methoxy...)
Affinity DataIC50: 55nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160506(US9682968, Example-40 | US10093663, Example 40)
Affinity DataIC50: 55nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251887(US9475806, 17-C)
Affinity DataIC50: 60nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159509(US9682968, Example-17-13 | US10093663, Example 17-...)
Affinity DataIC50: 63nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159379(US9682968, Example-17-8 | US10093663, Example 17-8)
Affinity DataIC50: 70nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289452(US10093663, Example 17-4)
Affinity DataIC50: 87nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251870(US9475806, 6-C b) (-))
Affinity DataIC50: 90nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251888(US9475806, 17-G)
Affinity DataIC50: 90nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251883(US9475806, 14-I b) (-))
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159382(US9682968, Example-17-10 | US10093663, Example 17-...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159841(US9682968, Example-17-22 | US10093663, Example 17-...)
Affinity DataIC50: 100nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289450(US10093663, Example 17-5 | US10093663, Example 17-...)
Affinity DataIC50: 120nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251872(US9475806, 7-D b) (-))
Affinity DataIC50: 130nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160501(US9682968, Example-38 | US10093663, Example 38)
Affinity DataIC50: 130nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM251869(US9475806, 5-B b) (-))
Affinity DataIC50: 140nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2017
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159303(US9682968, Example-13 | US10093663, Example 13)
Affinity DataIC50: 140nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159932(US9682968, Example-17-28 | US10093663, Example 17-...)
Affinity DataIC50: 160nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM289524(US10093663, Example 41 | Ethyl 4-((2S,4R)-1-((5-me...)
Affinity DataIC50: 165nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159157(US9682968, Example-5-4 | US10093663, Example 5-4)
Affinity DataIC50: 180nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159302(US9682968, Example-12 | US10093663, Example 12)
Affinity DataIC50: 230nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 165 total ) | Next | Last >>
Jump to: